Bayer Mycelex-3 "Preferred form v. Monistat-3" comparative ad not supported -- NAD.
This article was originally published in The Tan Sheet
Executive Summary
BAYER MYCELEX-3 "PREFERRED FORM v. MONISTAT-3" AD CLAIM UNSUBSTANTIATED as it "could be reasonably interpreted by consumers as a direct comparative claim between Mycelex-3 and [Johnson & Johnson's] Monistat-3, and...the data submitted by the advertiser was insufficient to support such a claim," the National Advertising Division of the Council of Better Business Bureaus concludes in its November NAD Case Reports. NAD urges Bayer either to cease using the claim or more clearly communicate that the claim is a comparison between all OTC cream yeast infection treatments versus other treatment forms and is based on total unit sales. J&J brought the claim to NAD's attention.